PT - JOURNAL ARTICLE AU - Ma, Khang AU - Nakajima, Hosei AU - Basak, Nipa AU - Barman, Arko AU - Ratnapriya, Rinki TI - Integrating explainable machine learning and transcriptomics data reveals cell-type specific immune signatures underlying macular degeneration AID - 10.1101/2024.10.26.24316189 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.26.24316189 4099 - http://medrxiv.org/content/early/2024/10/27/2024.10.26.24316189.short 4100 - http://medrxiv.org/content/early/2024/10/27/2024.10.26.24316189.full AB - Genome-wide association studies (GWAS) have established a key role of dysfunctional immune response in the etiology of Age-related Macular Degeneration (AMD). However, immune cells constitute a small proportion of the retina, and their role in AMD is not completely resolved. Here we develop an explainable machine learning pipeline using transcriptome data 453 donor retinas, identifying 81 genes distinguishing AMD from controls with an AUC-ROC of 0.80 (CI 0.70-0.92). These genes show enrichment for pathways involved in immune response, complement and extracellular matrix and connected to known AMD genes through co-expression networks and gene expression correlation. The majority of these genes were enriched in their expression within retinal glial cells, particularly microglia and astrocytes. Their role in AMD was further strengthened by cellular deconvolution, which identified distinct differences in microglia and astrocytes between normal and AMD. We corroborated these findings using independent single-cell data, where several of these candidate genes exhibited differential expression. Finally, the integration of AMD-GWAS data identified a common regulatory variant, rs4133124 at PLCG2, as a novel AMD-association. Collectively, our study provides molecular insights into the recurring theme of immune dysfunction in AMD and highlights the significance of glial cell differences as an important determinant of AMD progression.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is supported by Career Development Award from Research to Prevent Blindness (RPB) and New Investigator Award by BrightFocus Foundation to RR. RR is also supported by an Unrestricted grant from Research to Prevent Blindness (RPB) to Baylor College of Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe transcriptome data from 453 human donor retina used in this study are available in GEO (accession code GSE115828). Summary Statistics of advanced AMD is available at http://amdgenetics.org/ and early AMD is available for the download from www.genepi-regensburg.de/earlyamd. Single-cell retina data are available from GSE202747 and GSE130636 and single nuclei data was available under the accession code GSE221042.